NCT03297983View on ClinicalTrials.gov

M7583 Relative Bioavailability of Tablet Compared to Powder-in-capsule

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 9, 2017

Primary Completion Date

December 6, 2017

Study Completion Date

December 6, 2017

Conditions

Healthy

Interventions

DRUG

M7583

Subject will receive either M7583 PiC or M7583 tablet formulation orally under fasted conditions in part 1 followed by M7583 tablet formulation under fed condition in part 2 of the study.

Trial Locations (1)

89231

Nuvisan GmbH, Neu-Ulm

All Listed Sponsors

lead

Merck KGaA, Darmstadt, Germany

INDUSTRY

NCT03297983 - M7583 Relative Bioavailability of Tablet Compared to Powder-in-capsule | Biotech Hunter | Biotech Hunter